nach oben

Cardiovascular Toxicology

Erschienen in:

24.05.2017

Effects of Remifentanil Pretreatment on Bupivacaine Cardiotoxicity in Rats

verfasst von: Özcan Pişkin, Hilal Ayoğlu

Erschienen in: Cardiovascular Toxicology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Unintentional intravascular administration of bupivacaine may cause local anesthetic systemic toxicity (LAST). Although many systems are affected in LAST, the cardiovascular effects can be life-threatening. Remifentanil is a selective, ultra-short-acting, µ-opioid receptor agonist opioid. This study assessed the effects of combined pretreatment with intravenous lipid emulsion (ILE) and remifentanil on the cardiotoxicity caused by bupivacaine in an experimental model of anesthetized rats. The rats were divided into three groups. Group B received a saline pretreatment plus a bupivacaine, group L received ILE pretreatment plus a bupivacaine, and in group R, remifentanil was infused intravenously, plus ILE pretreatment plus a bupivacaine. The electrocardiogram tracing, invasive arterial pressure, and heart rate (HR) of rats were monitored continuously. Arterial blood gas analysis was performed in all groups. Arterial blood gas analysis revealed that the baseline pH (7.38 ± 0.31, 7.39 ± 0.41, and 7.37 ± 0.02 for groups B, L, and R, respectively), PaO₂ (198.5 ± 9.45, 196.1 ± 32.3, and 197.7 ± 9.25 mmHg, respectively), and PaCO₂ (37.8 ± 4.91, 37.4 ± 4.85, and 36.9 ± 4.42 mmHg, respectively) were similar in the groups (p > 0.05). Time to first alteration in QRS complex, time to first arrhythmia, time to 25, 50, and 75% reductions in HR, time to 25, 50, and 75% reductions in MAP, and time to asystole were recorded. Widening of the QRS complex was found 41.8 ± 16.6, 88.5 ± 7.91, and 103.0 ± 15.7 s after initiating the bupivacaine infusion in groups B, L, and R, respectively. Time elapsed until 25% reduction in HR was found 136.5 ± 50.7, 284.7 ± 31.7, and 292.0 ± 46.0 s for groups B, L, and R, respectively, and that until 25% reduction in MAP was found 101.7 ± 14.3, 245.0 ± 36.6, and 237.6 ± 52.6 s, respectively. Arrhythmia was observed after 135.2 ± 27.4, 172.4 ± 18.1, and 176.2 ± 23.0 s in groups B, L, and R, respectively. Finally, asystole occurred after 553.6 ± 74.4, 766.7 ± 64.8, and 800.1 ± 94.7 s in groups B, L, and R, respectively. This finding indicates that the survival time of rats administered pretreatment with ILE plus remifentanil and those given ILE was observed to be longer. Additionally, this study found that intravenous lipid emulsion plus remifentanil pretreatment did not result in better durations in terms of formation of bupivacaine intoxication and asystole compared to lipid pretreatment alone.

Groban, L. (2003). Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model. Regional Anesthesia and Pain Medicine, 28, 3–11.CrossRefPubMed

Clarkson, C. W., & Hondeghem, L. M. (1985). Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole. Anesthesiology, 62, 396–405.CrossRefPubMed

Litz, R. J., Roessel, T., Heller, A. R., & Stehr, S. N. (2008). Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection. Anesthesia and Analgesia, 106, 1575–1577.CrossRefPubMed

Oda, Y., & Ikeda, Y. (2013). Effect of lipid emulsion on the central nervous system and cardiac toxicity of bupivacaine and levobupivacaine in awake rats. Journal of Anesthesia, 27, 500–504.CrossRefPubMed

Shirole, R. L., Shirole, N. L., & Saraf, M. N. (2015). In vitro relaxant and spasmolytic effects of essential oil of Pistacia integerrima Stewart ex Brandis Galls. Journal of Ethnopharmacology, 168, 61–65.CrossRefPubMed

Nita, I. I., Hershfinkel, M., Lewis, E. C., & Sekler, I. (2015). A crosstalk between Na⁺ channels, Na⁺/K⁺ pump and mitochondrial Na⁺ transporters controls glucose-dependent cytosolic and mitochondrial Na⁺ signals. Cell Calcium, 57, 69–75.CrossRefPubMed

Lynch, C., 3rd. (1986). Depression of myocardial contractility in vitro by bupivacaine, etidocaine, and lidocaine. Anesthesia and Analgesia, 65, 551–559.PubMed

Weinberg, G. L., VadeBoncouer, T., Ramaraju, G. A., Garcia-Amaro, M. F., & Cwik, M. J. (1998). Pretreatment or resuscitation with a lipid infusion shifts the dose–response to bupivacaine-induced asystole in rats. Anesthesiology, 88, 1071–1075.CrossRefPubMed

Rosenblatt, M. A., Abel, M., Fischer, G. W., Itzkovich, C. J., & Eisenkraft, J. B. (2006). Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology, 105, 217–218.CrossRefPubMed

10.

ACMT. (2011). ACMT position statement: Interim guidance for the use of lipid resuscitation therapy. Journal of Medical Toxicology, 7(1), 81–82.CrossRef

11.

ASRA Checklist for treatment of local anesthetic systematic toxicity 2011Availlable from:https://www.asra.com/advisory-guidelines/article/3/checklist-for-treatment-of-local-anesthetic-systemic-toxicity. Accessed 29 December 2016.

12.

Hayes, B. D., Gosselin, S., Calello, D. P., Nacca, N., Rollins, C. J., Abourbih, D., et al. (2016). Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clinical Toxicology (Phila), 54, 365–404.CrossRef

13.

Hoegberg, L. C. G., Bania, T. C., Lavergne, V., Bailey, B., Turgeon, A. F., Thomas, S. H. L., et al. (2016). Systematic review of the effect of intravenous lipid emulsion therapy for local anesthetic toxicity. Clinical Toxicology (Phila), 54, 167–193.CrossRef

14.

Patel, S. S., & Spencer, C. M. (1996). Remifentanil. Drugs, 52, 417–427.CrossRefPubMed

15.

Peart, J. N., Gross, E. R., & Gross, G. J. (2005). Opioid-induced preconditioning: Recent advances and future perspectives. Vascular Pharmacology, 42, 211–218.CrossRefPubMed

16.

Yu, C. K., Li, Y. H., Wong, G. T., Wong, T. M., & Irwin, M. G. (2007). Remifentanil preconditioning confers delayed cardioprotection in the rat. British Journal of Anaesthesia, 99, 632–638.CrossRefPubMed

17.

Zhang, Y., Chen, Z.-W., Girwin, M., & Wong, T.-M. (2005). Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. Acta Pharmacologica Sinica, 26, 546–550.CrossRefPubMed

18.

Hanci, V., Karakaya, K., Yurtlu, S., Hakimoglu, S., Can, M., Ayoglu, H., et al. (2009). Effects of dexmedetomidine pretreatment on bupivacaine cardiotoxicity in rats. Regional Anesthesia and Pain Medicine, 34, 565–568.CrossRefPubMed

19.

Yurtlu, D. A., & Kaya, K. (2013). Ropivacaine, articaine or combination of ropivacaine and articaine for epidural anesthesia in cesarean section: A randomized, prospective, double-blinded study. Brazilian Journal of Anesthesiology, 63, 85–91.CrossRefPubMed

20.

Faccenda, K. A., & Finucane, B. T. (2001). Complications of regional anaesthesia Incidence and prevention. Drug Safety, 24, 413–442.CrossRefPubMed

21.

Felice, K., & Schumann, H. (2008). Intravenous lipid emulsion for local anesthetic toxicity: A review of the literature. Journal of Medical Toxicology, 4, 184–191.CrossRefPubMedPubMedCentral

22.

de La Coussaye, J. E., Eledjam, J. J., Brugada, J., & Sassine, A. (1993). Cardiotoxicity of local anesthetics. Cahiers d’Anesthesiologie, 41, 589–598.

23.

Cave, G., Harvey, M., Willers, J., Uncles, D., Meek, T., Picard, J., et al. (2014). LIPAEMIC report: Results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry. Journal of Medical Toxicology, 10, 133–142.CrossRefPubMedPubMedCentral

24.

Neal, J. M., Bernards, C. M., Butterworth, J. F. T., Di Gregorio, G., Drasner, K., Hejtmanek, M. R., et al. (2010). ASRA practice advisory on local anesthetic systemic toxicity. Regional Anesthesia and Pain Medicine, 35, 152–161.CrossRefPubMed

25.

Weinberg, G. L. (2010). Treatment of local anesthetic systemic toxicity (LAST). Regional Anesthesia and Pain Medicine, 35, 188–193.CrossRefPubMed

26.

Liu, P., Feldman, H. S., Covino, B. M., Giasi, R., & Covino, B. G. (1982). Acute cardiovascular toxicity of intravenous amide local anesthetics in anesthetized ventilated dogs. Anesthesia and Analgesia, 61, 317–322.PubMed

27.

Cho, H. S., Lee, J. J., Chung, I. S., Shin, B. S., Kim, J. A., & Lee, K. H. (2000). Insulin reverses bupivacaine-induced cardiac depression in dogs. Anesthesia and Analgesia, 91, 1096–1102.PubMed

28.

Vasques, F., Behr, A. U., Weinberg, G., Ori, C., & Di Gregorio, G. (2015). A review of local anesthetic systemic toxicity cases since publication of the american society of regional anesthesia recommendations: To whom it may concern. Regional Anesthesia and Pain Medicine, 40, 698–705.CrossRefPubMed

29.

Di Gregorio, G., Neal, J. M., Rosenquist, R. W., & Weinberg, G. L. (2010). Clinical presentation of local anesthetic systemic toxicity: A review of published cases, 1979 to 2009. Regional Anesthesia and Pain Medicine, 35, 181–187.CrossRefPubMed

30.

Kim, H. S., Cho, J. E., Hong, S. W., Kim, S. O., Shim, J. K., & Kwak, Y. L. (2010). Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. Physiological Research, 59, 347–356.PubMed

31.

Wong, G. T. C., Li, R., Jiang, L. L., & Irwin, M. G. (2010). Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiologica Scandinavica, 54, 510–518.CrossRefPubMed

32.

Zhang, Y., Irwin, M. G., Wong, T. M., Chen, M., & Cao, C. M. (2005). Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. Anesthesiology, 102, 371–378.CrossRefPubMed

33.

Tanaka, K., Kersten, J. R., & Riess, M. L. (2014). Opioid-induced cardioprotection. Current Pharmaceutical Design, 20(36), 5696–5705.CrossRefPubMedPubMedCentral

34.

Glass, P. S., Gan, T. J., & Howell, S. (1999). A review of the pharmacokinetics and pharmacodynamics of remifentanil. Anesthesia and Analgesia, 89, 7–14.CrossRef

35.

Reid, J. E., & Mirakhur, R. K. (2000). Bradycardia after administration of remifentanil. British Journal of Anaesthesia, 84, 422–423.CrossRefPubMed

36.

Kurdi, O., Deleuze, A., Marret, E., & Bonnet, F. (2001). Asystole during anaesthetic induction with remifentanil and sevoflurane. British Journal of Anaesthesia, 87, 943.PubMed

Titel: Effects of Remifentanil Pretreatment on Bupivacaine Cardiotoxicity in Rats
verfasst von: Özcan Pişkin
Hilal Ayoğlu
Publikationsdatum: 24.05.2017
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 1/2018
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-017-9413-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effects of Remifentanil Pretreatment on Bupivacaine Cardiotoxicity in Rats

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

QT Prolongation as an Isolated Long-Term Cardiac Manifestation of Dichlorvos Organophosphate Poisoning in Rats

Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats

The Cardiovascular Effect of Single Injection and Toxicologic Effects of Repetitive 2-Week Intravenous Administration of Activin A/BMP-2 Chimera in Beagle Dog

Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents

Exercise and Doxorubicin Treatment Modulate Cardiac Mitochondrial Quality Control Signaling

Cardiovascular Effects and Fatality May Differ According to the Formulation of Glyphosate Salt Herbicide